保观 |聚焦保险创新国内篇行业动态三生制药与百利天恒达成临床研究合作2月14日,百利天恒宣布,公司与三生制药近日达成《战略合作协议》,双方将共同推进BL-B01D1和707联合用药,在国内用于实体瘤的治疗,探索双抗+双抗ADC在肿瘤治疗上未被发掘的潜在价值。资料显示,BL-B01D1是百利天恒自主研发的全球首创也是唯一进入临床阶段的靶向EGFR×HER3的双抗ADC,正在中国和美国进行约30项针对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.